Laboratory Evaluation for Bleeding Disorders
For evaluating bleeding and coagulation abnormalities, order a complete blood count with platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen as initial hemostasis tests, then add von Willebrand factor antigen (VWF:Ag), von Willebrand factor ristocetin cofactor activity (VWF:RCo), and factor VIII activity if mucocutaneous bleeding is present or suspected. 1
Initial Hemostasis Testing (First-Line)
The foundational laboratory workup should include:
- Complete blood count (CBC) with platelet count and differential - Essential to identify thrombocytopenia or thrombocytosis as potential bleeding causes 1, 2
- Prothrombin time (PT) - Screens for extrinsic pathway defects and factor VII deficiency 1
- Activated partial thromboplastin time (aPTT) - Detects intrinsic pathway abnormalities including factors VIII, IX, XI, and XII deficiencies 1
- Fibrinogen level (Clauss method preferred) - Identifies hypofibrinogenemia or dysfibrinogenemia 2
Critical caveat: PT and aPTT have remarkably low sensitivity (1.0-2.1%) for detecting clinically significant bleeding disorders in patients referred for bleeding evaluation 3, 4. These tests should not be used to predict bleeding risk but rather to identify specific coagulation factor deficiencies when abnormal.
Von Willebrand Disease Screening (Add Immediately if Mucocutaneous Bleeding Present)
When the bleeding history suggests mucocutaneous bleeding (epistaxis, gingival bleeding, menorrhagia, easy bruising), add these three tests simultaneously with initial hemostasis tests:
- VWF antigen (VWF:Ag) - Quantifies von Willebrand factor protein 1
- VWF ristocetin cofactor activity (VWF:RCo) - Measures functional activity 1
- Factor VIII coagulant activity (FVIII) - Often reduced in von Willebrand disease 1
This VWD screening panel increases diagnostic sensitivity from 3.7% to 8.5% compared to basic coagulation tests alone 4. A VWF:RCo to VWF:Ag ratio below 0.5-0.7 suggests type 2 VWD and warrants VWF multimer analysis 1.
Additional First-Line Tests Based on Clinical Context
For Suspected Bleeding Disorders in Children
Multiple guidelines recommend checking these systematically or based on clinical context 5:
- Complete blood count with platelets - Recommended systematically by most guidelines
- Standard coagulation panel (aPTT, PT, INR, fibrinogen) - To rule out coagulation factor deficiencies
- Blood smear - Evaluate platelet morphology and count 6
For Obstetric Hemorrhage
In postpartum bleeding scenarios, monitor 7:
- Hemoglobin levels - Serial monitoring during active hemorrhage
- Platelet count
- Prothrombin time and aPTT
- Fibrinogen levels - A fibrinogen concentration below 2 g/L predicts progression to massive PPH requiring transfusion 7
Second-Line Testing (When Initial Tests Are Normal but Bleeding Suspicion Remains)
If first-line testing is normal but clinical suspicion for a bleeding disorder persists, proceed with 6, 2:
Advanced Coagulation Factor Assays
- Factor VIII and IX levels - For hemophilia A and B 5
- Von Willebrand activity with factors XI and XIII - For rarer factor deficiencies 5
- Factors II, V, VII, X, XIII - When unexplained bleeding continues 2
Platelet Function Testing
- Light transmission aggregometry (LTA) with multiple agonists (epinephrine, ADP, collagen, arachidonic acid, ristocetin) - Sensitivity of 26% for detecting bleeding disorders, significantly higher than coagulation screening 6, 4
- Platelet granule release assays (ATP/ADP measurement) 6
- Flow cytometry for platelet surface glycoproteins (GPIIb/IIIa, GPIb, GPIb/IX) 6
Specialized Testing
- Fibrinolysis assays - For suspected hyperfibrinolysis 2
- α2-antiplasmin and plasminogen activator inhibitor-1 (PAI-1) - For delayed-onset bleeding 8, 9
- Factor XIII activity - Critical for delayed bleeding after trauma or surgery 8, 9
Algorithmic Approach
Step 1: Obtain CBC with platelets, PT, aPTT, and fibrinogen on all patients with bleeding concerns
Step 2: If mucocutaneous bleeding history is present, simultaneously add VWF:Ag, VWF:RCo, and FVIII
Step 3: If abnormalities detected, perform specific factor assays or mixing studies (50:50 mix) to differentiate factor deficiency from inhibitors
Step 4: If all initial tests normal but bleeding history convincing, proceed to platelet function testing (LTA with multiple agonists) and advanced factor assays
Step 5: Consider rare bleeding disorder workup (factor XIII, α2-antiplasmin, PAI-1) only when severe unexplained bleeding persists despite negative initial and second-line testing
Important Clinical Pitfalls
Do not use PT/aPTT for preoperative bleeding risk prediction - These tests have extremely poor sensitivity for clinically significant bleeding disorders and should not guide prophylactic transfusion decisions 3, 4
Recognize developmental hemostasis in neonates - Coagulation factor levels, natural anticoagulants, and platelet function vary significantly with gestational and postnatal age, requiring age-appropriate reference ranges 10
Avoid over-reliance on coagulation tests in liver disease - PT and aPTT do not accurately reflect hemostasis in cirrhosis and should not predict bleeding risk; viscoelastic testing (thromboelastography/thromboelastometry) provides better perioperative guidance 7, 11
Consider acquired causes - Before extensive inherited bleeding disorder workup, exclude medications (anticoagulants, antiplatelet agents), systemic diseases, liver disease, vitamin K deficiency, and disseminated intravascular coagulation 6, 7